These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 29342381)

  • 1. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.
    Kyle RA; Larson DR; Therneau TM; Dispenzieri A; Kumar S; Cerhan JR; Rajkumar SV
    N Engl J Med; 2018 Jan; 378(3):241-249. PubMed ID: 29342381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.
    Dispenzieri A; Katzmann JA; Kyle RA; Larson DR; Melton LJ; Colby CL; Therneau TM; Clark R; Kumar SK; Bradwell A; Fonseca R; Jelinek DF; Rajkumar SV
    Lancet; 2010 May; 375(9727):1721-8. PubMed ID: 20472173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation.
    Naina HV; Harris S; Dispenzieri A; Cosio FG; Habermann TM; Stegall MD; Dean PG; Prieto M; Kyle RA; Rajkumar SV; Leung N
    Am J Nephrol; 2012; 35(4):365-71. PubMed ID: 22473253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later.
    Kyle RA; Therneau TM; Rajkumar SV; Larson DR; Plevak MF; Melton LJ
    Mayo Clin Proc; 2004 Jul; 79(7):859-66. PubMed ID: 15244381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A long-term study of prognosis in monoclonal gammopathy of undetermined significance.
    Kyle RA; Therneau TM; Rajkumar SV; Offord JR; Larson DR; Plevak MF; Melton LJ
    N Engl J Med; 2002 Feb; 346(8):564-9. PubMed ID: 11856795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal gammopathy of undetermined significance.
    Kyle RA; Rajkumar SV
    Clin Lymphoma Myeloma; 2005 Sep; 6(2):102-14. PubMed ID: 16231848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical characteristics and progression risk factors for patients with monoclonal gammopathy of undetermined significance].
    Guan A; Shen KN; Zhang L; Cao XX; Su W; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2023 Feb; 44(2):137-140. PubMed ID: 36948868
    [No Abstract]   [Full Text] [Related]  

  • 9. The Role of Diagnosis and Clinical Follow-up of Monoclonal Gammopathy of Undetermined Significance on Survival in Multiple Myeloma.
    Sigurdardottir EE; Turesson I; Lund SH; Lindqvist EK; Mailankody S; Korde N; Björkholm M; Landgren O; Kristinsson SY
    JAMA Oncol; 2015 May; 1(2):168-74. PubMed ID: 26181017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal Gammopathy of Undetermined Significance (MGUS)Monoclonal Gammopathy of Undetermined Significance (MGUS).
    Viera S; Ludek P; Zdeněk A; Marta K; Martin Š; Sabina Š; Zdeněk K
    Klin Onkol; 2018; 31(4):270-276. PubMed ID: 30541309
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z; Krejčí M; Pour L; Sevčíková E; Křivanová A; Rehák Z; Koukalová R; Cermáková Z; Vaníček J; Sevčíková S
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany.
    Eisele L; Dürig J; Hüttmann A; Dührsen U; Assert R; Bokhof B; Erbel R; Mann K; Jöckel KH; Moebus S;
    Ann Hematol; 2012 Feb; 91(2):243-8. PubMed ID: 21789623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Cesana C; Klersy C; Barbarano L; Nosari AM; Crugnola M; Pungolino E; Gargantini L; Granata S; Valentini M; Morra E
    J Clin Oncol; 2002 Mar; 20(6):1625-34. PubMed ID: 11896113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-MGUS Diagnosis Serum Monoclonal-Protein Velocity and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma.
    Chang SH; Gumbel J; Luo S; Thomas TS; Sanfilippo KM; Luo J; Colditz GA; Carson KR
    Cancer Epidemiol Biomarkers Prev; 2019 Dec; 28(12):2055-2061. PubMed ID: 31501149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.
    Katzmann JA; Clark R; Kyle RA; Larson DR; Therneau TM; Melton LJ; Benson JT; Colby CL; Dispenzieri A; Landgren O; Kumar S; Bradwell AR; Cerhan JR; Rajkumar SV
    Leukemia; 2013 Jan; 27(1):208-12. PubMed ID: 22781594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining the clinical significance of monoclonal gammopathy of undetermined significance: a SEER-Medicare population analysis.
    Go RS; Gundrum JD; Neuner JM
    Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):177-186.e4. PubMed ID: 25445471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance.
    Rajkumar SV; Kyle RA; Therneau TM; Clark RJ; Bradwell AR; Melton LJ; Larson DR; Plevak MF; Katzmann JA
    Br J Haematol; 2004 Nov; 127(3):308-10. PubMed ID: 15491291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenström's macroglobulinemia (SWM).
    Kyle RA; Dispenzieri A; Kumar S; Larson D; Therneau T; Rajkumar SV
    Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):74-6. PubMed ID: 21454195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.
    Kleinstern G; Larson DR; Allmer C; Norman AD; Muntifering G; Sinnwell J; Visram A; Rajkumar V; Dispenzieri A; Kyle RA; Slager SL; Kumar S; Vachon CM
    Blood Cancer J; 2022 Apr; 12(4):67. PubMed ID: 35440099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.
    Varettoni M; Zibellini S; Boveri E; Klersy C; Candido C; Rattotti S; Ferretti VV; Defrancesco I; Mangiacavalli S; Nizzoli ME; Flospergher E; Zerbi C; Bergamini F; Benvenuti P; Brociner M; Merati G; Paulli M; Arcaini L
    Br J Haematol; 2019 Nov; 187(4):441-446. PubMed ID: 31276195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.